PhosLo, in both capsule and gelcap formulations, has been approved for the control of hyperphosphatemia in end stage renal failure in adult patients. Patients suffering from kidney disease may experience increased blood levels of phosphate, which plays a pivotal role in causing secondary hyperpara-thyroidism associated with osteodystrophy and soft-tissue calcification. The rate of removal of phosphate by dialysis or by dietary manipulation is insufficient.
Studies have confirmed that using calcium acetate as a phosphorus binder will control serum phosphorus levels in most dialysis outpatients.
Adverse events associated with the use of PhosLo capsules or gelcaps may include (but are not limited to) the following:
PhosLo (calcium acetate) binds to the phosphate taken in through one's diet to form insoluble calcium phosphate. This is then excreted from the body without being absorbed.
For additional information on PhosLo, please visit Braintree Laboratories.